KOL Views Preview: How competitive are allogeneic CAR-T cells looking?

CRISPR Therapeutics plans to expand the Phase I CARBON trial into a pivotal study after reporting that single doses of CTX110 achieved an overall response rate of 58% in relapsed or refractory CD19+ B-cell malignancies. However, the complete response rate fell from an initial 38% to 21% only six months after treatment with the allogeneic anti-CD19 CAR-T therapy, which will raise questions about durability and re-dosing.

To provide FirstWord readers with rapid feedback on the competitive profile of allogeneic CAR-T cell therapies, we are hosting an expert call with a key opinion leader (KOL) later this week or early next week.

Key topics that will be discussed during the call include, among other things… what stands out most about CRISPR’s recent CARBON readout; how does CTX110’s initial efficacy look relative to both your expectations and autologous anti-CD19 CAR-T cell products; how concerning is the drop-off in complete response rate after six months; do you think a second dose will improve remission rates and might additional dosing be a possibility; what kind of complete response rate are you hoping to see with re-dosing; are there any notable differences in safety between CTX110 and autologous therapies; might an allogenic product remain competitive even with a lower response rate due to other advantages, and if so how much of a reduction would physicians and/or patients be willing to accept; does the recent FDA clinical hold placed on an allogeneic cell therapy from Allogene due to a “chromosomal abnormality” have any impact on your perception of CTX110 or other allogeneic CAR-T programmes; aside from the safety signal, are there any notable differences in the performance thus far for CTX110 and Allogene’s ALLO-501A; where do you see allogeneic CAR-T cell therapies like CTX110 fitting into the treatment paradigm for B-cell lymphomas in the short- and long-term; are you more or less optimistic about allogeneic CAR-T cell therapies addressing targets like BCMA and CD70?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the use of allogeneic CAR-T cell therapies.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord Pharma would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.